Gyre Therapeutics, Inc. Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure
Gyre Therapeutics, Inc. (GYRE) reported Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure of $21.40 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Notes
us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure · last filed 2023-03-30
- Gyre Therapeutics, Inc. concentration risk, credit risk, financial instrument, maximum exposure for fiscal 2022 was $21.40M.
| Period end | Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure 12 month |
|---|---|
| 2022-12-31 | $21.40M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |